TNF and Recurrent upper respiratory tract infections: In this study, analysis of the occurrence of complications in patients who developed ILD as an adverse event upon administration of the TNF‐α inhibitors adalimumab, infliximab, and certolizumab showed complications such as tuberculosis and upper respiratory tract infection, acute respiratory failure, and dyspnea, respectively.